Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

CHICAGO -- An investigational, oral small-molecule GLP-1 receptor agonist improved glycated hemoglobin levels in adults with ...

Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) American Diabetes Association (ADA) 85th Scientific Sessions Conference June 20, 2025 8:15 PM ET James Markmann - Corporate Participant Michael ...

The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Women who replaced their lunchtime diet beverage with water had greater weight loss and achieved diabetes remission compared ...

Diabetes pills could hit Australian shelves within years, offering an alternative to popular injectable treatments such as ...

Developments from two studies highlighting the potential for machine learning leveraging artificial intelligence (AI) technology to improve early-stage identification of type 1 diabetes were presented ...

Most in a small group of patients receiving a stem cell-based infusion no longer needed insulin, but the drug may not suit those with more manageable type 1 diabetes.